Navigation

Navigation

Physician Profile


<< Previous Physician | Return to Search Results | New Search | Next Physician >>


David W. Ollila, MD

Professor

Department of Surgery
    Division of Surgical Oncology and Endocrinology

Services:
Cancer Services, Divisional Programs, Endocrine Surgery
Cancer Services, Multidisciplinary Clinical Services, Breast Center, Surgical Oncology
Cancer Services, Multidisciplinary Clinical Services, Gastrointestinal Oncology Program, Surgery
Cancer Services, Multidisciplinary Clinical Services, Leukemia, Lymphoma and Myeloma Program, Surgical Oncology
Cancer Services, Multidisciplinary Clinical Services, Melanoma Program, Program Director
Cancer Services, Multidisciplinary Clinical Services, Melanoma Program, Surgical Oncology
Surgery, Endocrine Surgery
Surgery, General Surgery
Surgery, Surgical Oncology
Cancer Services, Divisional Programs, General Surgery/Surgical Oncology

Procedures/Research:
General surgical oncology, applications of sentinel node technology, breast diseases, novel therapies for metastatic melanoma, endocrine surgery.
 
Clinical Appointment Phone:  919-966-9700

Website: http://www.med.unc.edu/surgonc/faculty
David W. Ollila, MD


Certifications
Surgery - Board Certified  (1996)


Education and Training
Medical School: MD, University of Cincinnati, Cincinnati, OH, 1990
Residency: Riverside Methodist Hospital, Columbus, OH, 1990 - 1995
Area: Surgery
Fellowship: John Wayne Cancer Institute, Santa Monica, CA, 1995 - 1997
Area: Surgical Oncology


Professional Positions
  1. Director, Sentinel Node Program, University of North Carolina-Chapel Hill, 2000

  2. Co-Director, Multidisciplinary Melanoma Program, University of North Carolina-Chapel Hill, 2000


Honors
  1. Alpha Omega Alpha, University of North Carolina-Chapel Hill, 2000


Publications
  1. Tumor doubling time: A selection factor for pulmonary resectin of metastatic melanoma
    Authors: (1) Ollila DW, Stern SL, Morton DL
    Journal of Surgical Oncology 69:206-211, 1998

  2. The role of intraoperative lymphatic mapping and lymphadenectomy in the management of patients with breast cancer
    Authors: (2)Ollila DW, Brenna MB, Giuliano AE
    Advances in Surgery 32:349-364, 1999

  3. Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma
    Authors: (3) Morton DL, Ollila DW, Hsueh EC, Essner R, Gupta RK
    CA Cancer Clinics 49:101-116, 1999

  4. Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging.
    Authors: (4)Turner RR, Ollila DW, Stern S, Giuliano AE
    American Journal of Surgical Pathology 23(3):263-267, 1999

  5. Parotid region lymphatic mapping and sentinel lymphadenectomy for cutaneous melanoma.
    Authors: (5) Ollila DW, Foshag LJ, Essner R, Stern SL, Morton DL
    Annals of Surgical Oncology 6(2):150-154, 1999

  6. Metastasectomy for recurrent Stage IV melanoma
    Authors: Ollila DW, Hsueh EC, Stern SL, Morton DL
    Journal of Surgical Oncology 71(4):209-213, 1999

  7. Letter to the Editor: Tumor doubling time and survival
    Authors: (7) Ollila DW, Morton DL
    Journal of Surgical Oncology 71(4):249, 1999

  8. Critical review of the sentinel node hypothesis
    Authors: (8) Morton DL, Ollila DW
    Surgeryh 126(5):815-819, 1999

  9. Lymphatic mapping in breast cancer: Case 1 commentary
    Authors: (9)Ollila DW
    Cancer Case Presentations: The Tumor Board 49:51-52, 2000

  10. Safety and efficacy of 4AC followed by Taxol plus Herceptin (H) in high risk breast cancer patients.
    Authors: (10) Care LA, Dees C, Sartor C, Ollila D, Stager S, Cance W, Graham M
    Proceedings of American Society of Clinical Oncology 20:1856a, 2001


Physician Referral:
You can request a physician referral by calling UNC HealthLink at (919) 966-7890,
8:30 a.m. to 5 p.m., Monday through Friday.